We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
1ADNB | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
1ADO | AdAlta Limited | 0.002 | 0.00 | 0.00% | 0.00 | 0 |
1ADOA | AdAlta Limited | 0.001 | 0.00 | 0.00% | 0.00 | 0 |
1AE | Aurora Energy Metals Ltd | 0.081 | 0.00 | 0.00% | 0.00 | 0 |
1ADNA | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
1ADN | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
14D | 1414 Degrees Limited | 0.067 | 0.00 | 0.00% | 0.00 | 0 |
14DN | 1414 Degrees Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
14DO | 1414 Degrees Limited | 0.008 | 0.00 | 0.00% | 0.00 | 0 |
1AD | AdAlta Limited | 0.026 | 0.00 | 0.00% | 0.00 | 0 |
13S | 13 Seeds Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
The offering is comprised of 61,538,461 shares of the Company’s common stock (or pre-funded warrants in lieu of shares of common stock). Each share of common stock or pre-funded warrant will be sold with one Series A Warrant to purchase one share of common stock at an exercise price of $0.22 per share (the “Series A Warrants”) and one Series B Warrant to purchase one share of common stock at an exercise price of $0.22 per share or, pursuant to an alternative cashless exercise option, three shares of common stock at a price of $0.001 per share (the “Series B ...
Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee Review SAN DIEGO, June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, ...
VANCOUVER, BC, June 5, 2024 /PRNewswire/ -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) ("Siyata" or the "Company"), a global developer and vendor of Push-to-Talk (PTT) over Cellular (PoC) handsets and accessories, today announced its partnership with JD Telecom, a premier telecom solutions provider of commercial-grade vehicle solutions and a strategic distribution partner for T-Mobile, to expand distribution of its SD7 handsets, VK7 Vehicle Kits and related components.
TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeks Eighty percent (80%) of ICI naïve patients with advanced MCC who failed to respond to pembrolizumab or avelumab therapy achieved a durable Complete Response (CR), pathologic CR or Partial Response (PR) following IFx-2.0 therapy and rechallenge with an anti-PD(L)-1 checkpoint inhibitor Data presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, Fla. and SAN DIEGO, June 3, 2024 /PRNewswire/ -- TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy and ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 71,139.53 | 509.95 | 0.72% | 1.4T | 4,322,318,554 |
ETH | Ethereum | 3,858.66 | 28.66 | 0.75% | 464.42B | 2,232,831,118 |
BNB | Binance Coin | 694.28 | 51.74 | 8.05% | 109.45B | 713,529,314 |
USDT | Tether USD | 1.00 | 0.00 | 0.00% | 97.84B | 241,370,414 |
SOL | Solana | 173.32 | 8.24 | 4.99% | 76.48B | 868,411,581 |
STETH | stETH | 3,841.25 | 63.01 | 1.67% | 37.77B | 6,439,811 |
XRP | Ripple | 0.5266 | 0.0032 | 0.61% | 28.75B | 236,357,997 |
USDC | USD Coin | 0.9999 | -0.0001 | -0.01% | 28.07B | 872,984,303 |
TONCOIN | Wrapped TON Coin | 7.36 | 0.012401 | 0.17% | 25.58B | 270,809,982 |
DOGE | Dogecoin | 0.16369 | 0.00569 | 3.60% | 23.46B | 229,888,000 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions